Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca sees level performance in 2010

AstraZeneca sees level performance in 2010

28th January 2011

AstraZeneca has published its financial report for 2010, hailing the resilience of its business in difficult market conditions.

The company's revenue total for the year was $33.27 billion (20.94 billion pounds), broadly level with the amount generated last year, despite the impact of patent expiries and government pricing initiatives.

It credited this to the continuing strength of key brands such as Crestor, Symbicort and Seroquel XR, all of which saw double-digit sales growth, as well as its growing presence in emerging markets.

The firm has also been able to further the clinical development of several important treatments, including Brilinta, Onglyza and Vimovo.

David Brennan, chief executive officer of AstraZeneca, said: "This performance, combined with disciplined management of the business, enabled us to deliver increased earnings, increase the dividend and return residual cash to shareholders through share repurchases."

Earlier this month, the company agreed a new alliance with Cancer Research UK to conduct trials of experimental oncology therapies.ADNFCR-8000103-ID-800370818-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.